Exane Derivatives’s Radius Health, Inc. RDUS Stock Holding History

Exane Derivatives’s Portfolio RDUS Stock Details RDUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1	Closed	-$18	–	754
2018 Q3	$18	Hold	1	–	–	﹤0.01%	679
2018 Q2	$30	Hold	1	–	–	﹤0.01%	655
2018 Q1	$34	Sell	1 -31	-97%	-$1.12K	﹤0.01%	590
2017 Q4	$1.02K	Sell	32 -1,615	-98%	-$50.7K	﹤0.01%	484
2017 Q3	$63.5K	Buy	1,647 +1,599	+3,331%	+$62.8K	0.01%	288
2017 Q2	$2.17K	Buy	+48	New	+$1.83K	﹤0.01%	449
2016 Q4	–	Sell	-48,914	Closed	-$2.65M	–	689
2016 Q3	$2.65M	Buy	+48,914	New	+$2.49M	0.4%	60

Other funds holding RDUS

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Exane Derivatives's RDUS Position: Q4 2018 in Review

Exane Derivatives sold out of Radius Health, Inc. (RDUS) in Q4 2018, closing a stake of 1 share — an estimated $18 sold.

Exane Derivatives first reported a position in RDUS in Q3 2016 and held it in 7 quarters. The position peaked at $2.65M in Q3 2016. 123 funds tracked by Wall St. Rank hold RDUS as of Q4 2018.

Exane Derivatives reported no remaining Radius Health, Inc. position as of Q4 2018 after selling out during the quarter.
Exane Derivatives sold 1 Radius Health, Inc. share in Q4 2018, an estimated $18.
Exane Derivatives first reported a position in Radius Health, Inc. in Q3 2016 and held it in 7 quarters.
Exane Derivatives's Radius Health, Inc. position peaked at $2.65M in Q3 2016.
123 funds tracked by Wall St. Rank held Radius Health, Inc. as of Q4 2018.

Based on Exane Derivatives's 13F filing for Q4 2018, filed 31 Jan 2019.